Current Price{{movement}} {{quote.Last.toFixed(3) == 0.000 ? quote['CF CLOSE'].toFixed(3) : quote.Last.toFixed(3)}} (20 minute delay)
Today's Change {{quote['Net Change'].toFixed(3)}} ({{quote['% Change']}}%) Market is currently: {{(quote['Price Qualifier Code'] == 'OPN' || quote['Price Qualifier Code'] == 'SUS') ? "OPEN" : "CLOSED"}}
Open {{quote['Opening Price'].toFixed(3)}} Prev Close {{quote['Historic Close'].toFixed(3)}}
Today's High {{quote["Today's High"].toFixed(3)}} Today's Low {{quote["Today's Low"].toFixed(3)}}
Broker Consensus

No Data Available

  • Sell
  • Reduce
  • Hold
  • Buy
  • Strong Buy

Admedus Ltd (AHZ)
is a publicly listed company on the Australian Securities Exchange (ASX).


General Overview

About Admedus

Admedus is a diversified healthcare company with activities that are focused on areas of medical need to help patients who currently suffer reduced outcomes that adversely affect their quality of life.


AHZAdmedus has four key strategic business drivers that support our vision. Admedus are:

Investing in unique research programs by partnering with world-class experts to develop new medical technologies with global potential. World renowned Professor Ian Frazer is leading the development of a new range of therapeutic vaccines that have the ability to treat infectious diseases and some cancers.

Commercialising their own innovative technologies. The first product from their regenerative medicine program based on the proprietary ADAPT® tissue engineering process developed by Professor Leon Neethling has recently been launched into Europe, with sales being driven via their own sales and distribution business.

Acquiring strategic and synergistic assets to grow their product and service offerings. Admedus are continually assessing new opportunities to add to the Admedus portfolio to enhance their pipeline and add to shareholder value.

Expanding Admedus' revenue from their existing medical sales, marketing and distribution business. The growing healthcare market provides a strong platform for continued expansion into new and existing market segments as well as the opportunity to develop new products and services.


Admedus Ltd came into being in November 2013 as part of a global branding strategy and name change for ASX listed Allied Healthcare Group Ltd. The entry of the company into key markets in Europe and the plan to enter the US market early in 2014 required a clearly defined company name that has the ability to differentiate from other existing businesses. Allied Healthcare Group Ltd which was established in June 2011, through the merger of Allied Medical Ltd an unlisted public company and bioMD Ltd an ASX listed company (ASX: BOD).

The merger created a diversified healthcare group with assets in research & development, products in advanced clinical trials ready for commercialisation and a successful sales, marketing and medical device distribution business.

Listed on the ASX in 2004, bioMD acquired and had successfully developed the assets of regenerative tissue engineering company Celxcel.

Allied Medical Ltd was originally spun out of Fortescue Metals Group Limited (FMG) and became an independent entity in November 2005.

Allied's growth strategy was founded upon leveraging its core competencies in sales, distribution and commercialisation to support its investments in growth areas – sectors identified as having the potential to make a significant and positive contribution in the healthcare sector.

In 2008, Allied identified a partnership to gain entry in the growing vaccine market with a right to acquire a majority shareholding in Coridon Pty Ltd (Coridon), a company founded by Professor Ian Frazer, Australian of the Year 2006. Professor Frazer is well recognised for his ground breaking research that led to Merck & Co.'s highly successful cervical cancer vaccine, Gardasil®.

The Coridon partnership fitted well with Allied's long term strategic goal of creating shareholder value through identifying opportunities and investing in innovative technologies that have global potential with world class research expertise.

In 2010, the Allied expanded its sales and distribution business with the acquisition of Medevco Pty Ltd. Medevco was an Australian-based supplier and distributor of medical devices and had an existing sales, marketing, logistics and technical service footprint across Australia and New Zealand.



CardioCel® is an adapted collagen cardiovascular scaffold. It is the first of a suite of implantable tissues generated by their ADAPT® tissue engineering process, which offers medical professionals a potential improvement over the products they currently use.

This product is changing patients' lives across the world. Surgeons at medical centres throughout Europe, the US, Australia and Singapore are using CardioCel®, giving hope to patients with heart defects and those in need of heart valve, vessel and cardiovascular repairs.

CardioCel® also has licensing approval in Canada.

This product also has the potential to treat other conditions which benefit from the use of a tissue scaffold.

Manufactured to the highest international standards at their bio-manufacturing facility in Perth, Western Australia, CardioCel® is making a difference to patients and their families.

Regenerative Tissue Engineering

Their tissue engineering technology is based on the patented ADAPT® process that produces implantable tissue scaffolds for use in soft tissue repair as well as for the production of replacement tissue heart valves.

The ADAPT® technology, when applied to xenograft tissues produces unique implantable tissue scaffolds that are not only compatible with the human body, but most notably overcome many of the problems associated with existing tissue bio-implants currently in use.

With the potential for a product lifespan free from calcification, clinicians may be able to intervene across a broader age spectrum and provide their patients with a solution for life.


Admedus delivers the latest medical technology, products and devices to the healthcare sector. Each product in their range is carefully selected to meet the highest standards of quality, durability and reliability. Value is one of their company's core values and they endeavour to provide this to the medical professionals who select Admedus to deliver the tools they need to provide the very best healthcare available. Admedus also value relationships among their highest priorities – ensuring their business partners feel supported and valued. Their range of Medical Products reflects the very latest technology from the world's most experienced medical manufacturers and developers.

Other Products

Infusion Solutions

AHZFrom a full hospital system where high precision and reliability are critical, getting patients mobile and out of hospital more quickly, or managing post-operative pain more effectively, they have a tailored solution for you.

  • Whole-of-Hospital Infusion Systems
  • Ambulatory Infusion Devices
  • Connectors

Blood Pressure Management

AHZClinically validated non-invasive blood pressure products for difficult environments. Their specialised systems are designed to monitor blood pressure without interrupting your patients' daily routine

  • Stress BP
  • Resting BP
  • Ambulatory BP


AHZA simple but effective tool for amniotomy

  • Amniotomy


Urinary and surgical site catheters to support your procedures

  • Urinary Catheter
  • Surgical Site Catheter

Contact Info

Admedus Ltd

Level 1
197 Adelaide Terrace
Perth, WA
AU Australia, 6000

Phone: +61 8 9266 0100
Fax: +61 8 9266 0199

Click here to view the interactive map
Admedus Ltd Google Map
Admedus Ltd Google Map

No Share Registry Found

Important Information

The General Overview, Services, Products and Projects information for this profile was last edited on 31 May 2016.

All Financial Data is provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Share Prices nor any independent data provider is liable for any informational errors, omissions or other defects, incompleteness, or delays, or for any actions taken in reliance on Financial Data.

Please read our Terms & Conditions and Disclaimer Statement for further information.




Report a bug